Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to' returned 2 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom The 2011 ASCO (American Society of Clinical Oncology) Annual Meeting - Post Conference Review and Analysis   GlobalData, June 2011, Pages: 82 to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the Phase III CLASSIC 1 trial 2.8.4 Sequential azacitidine and lenalidomide in elderly AML Tumor Markers: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers   Venture Planning Group, June 2011, Pages: 1200 SR, and others 4. Biochips/Microarrays 5. Chromosome Analysis a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant Lymphomas Lymphoid Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets2    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network